30 years on, AstraZeneca sees healthy future

Since those earlier days, AstraZeneca has ramped up investment in China, constructing an efficient supply network. To date, the company has provided nearly 70 countries and regions with high-quality medicines made in China.

Entering its third decade, the biopharmaceutical company continued expanding its presence in China and worked on the building of a health innovation ecosystem, which includes the China Commercial Innovation Center, the International Life Science Innovation Campus and the medical industry AZ-CICC Fund.

"China has become AstraZeneca's second-largest market in the world and an important growth driver," said Michael Lai, general manager of AstraZeneca China. "We are always optimistic about the development potential in China and are looking forward to cooperating with our partners to contribute to a healthy China."